Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to -$18.6 million.

  • Anaptysbio's Change in Accured Expenses fell 65175.39% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.0 million, marking a year-over-year decrease of 232754.67%. This contributed to the annual value of -$33.8 million for FY2024, which is 40935.27% down from last year.
  • Anaptysbio's Change in Accured Expenses amounted to -$18.6 million in Q3 2025, which was down 65175.39% from -$22.3 million recorded in Q2 2025.
  • Over the past 5 years, Anaptysbio's Change in Accured Expenses peaked at $8.5 million during Q1 2023, and registered a low of -$40.0 million during Q4 2024.
  • In the last 5 years, Anaptysbio's Change in Accured Expenses had a median value of -$191000.0 in 2021 and averaged -$4.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 870666.67% in 2023, then tumbled by 257336.45% in 2024.
  • Over the past 5 years, Anaptysbio's Change in Accured Expenses (Quarter) stood at -$5.3 million in 2021, then skyrocketed by 190.81% to $4.8 million in 2022, then crashed by 131.0% to -$1.5 million in 2023, then tumbled by 2573.36% to -$40.0 million in 2024, then skyrocketed by 53.65% to -$18.6 million in 2025.
  • Its Change in Accured Expenses was -$18.6 million in Q3 2025, compared to -$22.3 million in Q2 2025 and -$24.0 million in Q1 2025.